Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06551051
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-09
Brief Title:
ADC-induced Neurotoxicity Treated With Duloxetine
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-arm Phase II Study of Duloxetine for the Treatment of Neurotoxicity Induced by Antibody-drug Conjugate
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Duloxetine may lessen peripheral neuropathy caused by chemotherapy It is not yet known whether duloxetine is effective in treating peripheral neuropathy caused by antibody-drug conjugate
PURPOSE This single arm phase II trial is studying duloxetine to see how well it works in treating peripheral neuropathy caused by antibody-drug conjugate in patients with cancer
PURPOSE This single arm phase II trial is studying duloxetine to see how well it works in treating peripheral neuropathy caused by antibody-drug conjugate in patients with cancer
Detailed Description:
This study is a single arm phase II study The study consisted of a screening period subjects signed informed consent up to no more than 28 days before the first treatment of the study a treatment period treatment termination was defined as termination of treatment for any reason such as imaging confirmation of disease progression intolerance of toxicities despite dose adjustments or early withdrawal for any reason and a follow up period consisting of an end-of-treatment visit a safety visit and a survival follow up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None